|
Á¦À̾ØÆÄÆ®³ÊÁîÄÚ¸®¾Æ(ÁÖ) |
[¿Ü±¹°èÁ¦¾à»ç] PV specialist
¼¿ï °³²±¸ | ´ëÇÐ(4³â) Á¹¾÷ |
PL/PV/PMS/MD |
2³â¡è |
ä¿ë½Ã |
04.19 |
|
|
JN Partners |
[À¯¸í±¹³»Á¦¾à»ç] PVÆÀÀå
¼¿ï °³²±¸ | ´ëÇÐ(4³â) Á¹¾÷ |
PL/PV/PMS/MD |
9³â¡è |
ä¿ë½Ã |
11.09 |
|
|
JN Partners |
[´ë±â¾÷¹ÙÀÌ¿À»ç] PV ¹× Çã°¡ ½Ç¹«±Þ
ÀÎõ ÀüÁö¿ª | ´ëÇÐ(4³â) Á¹¾÷ |
PL/PV/PMS/MD |
3³â¡è |
ä¿ë½Ã |
11.09 |
|
|
ÇÁ·ÎÇÚÁîÄÚ¸®¾Æ |
Áß°ßÁ¦¾à»ç °³¹ßÆÀ PV(¾à»ç) 2¸í
¼¿ï ±¸·Î±¸, °æ±â ¼º³²½Ã ¼öÁ¤±¸ | ´ëÇÐ(4³â) Á¹¾÷ |
PL/PV/PMS/MD |
2³â¡è |
ä¿ë½Ã |
02.26 |
|
|
Á¦À̾ØÆÄÆ®³ÊÁîÄÚ¸®¾Æ(ÁÖ) |
[À¯¸íÁ¦¾à»ç] PVÆÀ¿ø ȤÀº ÆÀÀå
¼¿ï ¼Ãʱ¸ | ´ëÇÐ(4³â) Á¹¾÷ |
PL/PV/PMS/MD |
3³â¡è |
ä¿ë½Ã |
04.25 |
|
|
K1partners |
[±¹³»Áß°ßÁ¦¾à»ç] °³¹ßºÎ ÆÀ¿ø ¹× ÆÀÀå ä¿ë(½ÅÀÔ¾à»ç ¹× °æ
¼¿ï ÀüÁö¿ª | ´ëÇÐ(4³â) Á¹¾÷ |
°³¹ß/RA/´ë°ü |
°æ·Â¹«°ü |
ä¿ë½Ã |
01.17 |
|
|
JN Partners |
[¿Ü±¹°èÁ¦¾àȸ»ç] PV°æ·ÂÀÚ/ ºñ¾à»ç °¡´É
¼¿ï ÀüÁö¿ª | ´ëÇÐ(4³â) Á¹¾÷ |
PL/PV/PMS/MD |
3³â¡è |
ä¿ë½Ã |
01.03 |
|
|
¿¢½º´ÙÀÓ(ÁÖ) |
Post-Marketing Surveillance (´ë¸®~°úÀå) - ±¹³» À¯¸í Á¦¾à
¼¿ï ÀüÁö¿ª | ´ëÇÐ(4³â) ÀçÇÐ |
PL/PV/PMS/MD |
5³â¡è |
ä¿ë½Ã |
06.01 |
|
|
JN Partners |
[¿Ü±¹°èÁ¦¾àȸ»ç] PV¾à»ç
¼¿ï ÀüÁö¿ª | ´ëÇÐ(4³â) Á¹¾÷ |
PL/PV/PMS/MD |
2³â¡è |
ä¿ë½Ã |
02.21 |
|
|
´õ ÈÞ¸Õ |
±¹³» À¯¸í»óÀåÁ¦¾à»ç PV ÆÀÀå±Þ Æ÷Áö¼Ç ASAP
¼¿ï Á¾·Î±¸ | ´ëÇÐ(4³â) Á¹¾÷ |
PL/PV/PMS/MD |
3³â¡è |
ä¿ë½Ã |
05.19 |
|
|
ÇÁ·ÎÇÚÁîÄÚ¸®¾Æ(ÁÖ) |
À¯¸í Á¦¾à ȸ»ç ÀÓ»ó°³¹ßÆÀ ºÎ¹® / Çã°¡ÀÓ»ó (´ë¸®,°úÀå±Þ)
¼¿ï ¼Ãʱ¸ | ´ëÇÐ(4³â) ÀçÇÐ |
PL/PV/PMS/MD |
5³â¡è |
ä¿ë½Ã |
05.19 |
|
|
ÆÄÀε崺·ÎµåÄÁ¼³Æà |
Patient Safety Lead (Â÷ºÎÀå±Þ) / ¿Ü±¹°è Á¦¾à»ç
¼¿ï ÀüÁö¿ª, ¼¿ï ÀüÁö¿ª | ´ëÇÐ(4³â) Á¹¾÷ |
PL/PV/PMS/MD |
6³â¡è |
ä¿ë½Ã |
05.03 |
|
|
À̳ë¼Ä¡ |
±Û·Î¹úÁ¦¾à»çPV, ±Û·Î¹úCRO RA
¼¿ï ÀüÁö¿ª | ´ëÇÐ(4³â) Á¹¾÷ |
°³¹ß/RA/´ë°ü |
3³â¡è |
ä¿ë½Ã |
08.30 |
|
|
KY Consulting Group |
[Á¦¾à´ë±â¾÷] ¾à¸®¿¬±¸½ÇÀå Ãʺù
°æ±â ¿ëÀνà | ´ëÇпø(¼®»ç) Á¹¾÷ |
PL/PV/PMS/MD |
10³â¡è |
ä¿ë½Ã |
01.22 |
|
|
HRKorea |
ÀǾàÇ° ¾à¹°°¨½Ã(PV) ¾÷¹«-±¹³» ¹× ÇØ¿Ü °³º°ÀÌ»ó»ç·Ê(ICSR)
¼¿ï ÀüÁö¿ª | ´ëÇÐ(4³â) Á¹¾÷ |
PL/PV/PMS/MD |
1³â¡è |
ä¿ë½Ã |
12.24 |
|